Epicutaneous Immunotherapy (EPIT®)

Our therapies are based on epicutaneous immunotherapy (EPIT®), a method inducing desensitization in allergic patients by delivering allergens through the skin.

We are developing an innovative immunotherapy technology platform that delivers biological compounds via intact skin.

In pre-clinical research, EPIT has been shown to induce a decrease of allergen-speific responses, including a decrease of allergen-specific responses and an increase of regualtory responses, including increase of allergen-specific IgG2a or IgG4, increase of regulatory T cells (Tregs).